Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Pfizer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Turning Point Therapeutics, Inc.
University Hospitals Coventry and Warwickshire NHS Trust
Revolution Medicines, Inc.
University of Edinburgh
Second Life Therapeutics
Novartis
Revolution Medicines, Inc.
Lund University Hospital
Pfizer
Metanoic Health Ltd.
Purdue University
Hoffmann-La Roche
New Day Diagnostics
Xijing Hospital
University of Sunderland
Thomas Jefferson University